Innovations in Digital Health, Diagnostics, and Biomarkers最新文献

Innovations and Limitations in Areca Nut Research: A Narrative Review 槟榔研究的创新与局限:述评

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2023-01-01 DOI: 10.36401/iddb-22-6

Jasper Hoi Chun Luong, Z. Kozlakidis, I. Cheong, Hui Wang

{"title":"Innovations and Limitations in Areca Nut Research: A Narrative Review","authors":"Jasper Hoi Chun Luong, Z. Kozlakidis, I. Cheong, Hui Wang","doi":"10.36401/iddb-22-6","DOIUrl":"https://doi.org/10.36401/iddb-22-6","url":null,"abstract":"\u0000 Areca nut (AN) and betel quid (BQ) products have been highly scrutinized by the scientific community in the last decade due to their classification by the International Agency for Research on Cancer as a group 1 carcinogen. However, neither the size of the user demographic nor the production levels of the product have varied greatly since the announcement, demonstrating that large demographics remain susceptible to oral cancer. Researching the demographic groups and their preferred AN or BQ products has helped provide an overview of the problem globally, from the diversity of products used to the users' demographic variation, including ethnicity, age group, wealth levels, and other factors. However, there is still a considerable lack of available sources related to AN or BQ usage in China, which is the region with the second-highest number of AN or BQ users. Recent studies of the chemical composition of AN or BQ products from different regions or with different preparation methods have reported varied chemical compositions. This is a novel view of the product because chemical components found to be carcinogenic, such as alkaloid arecoline, decreased under certain processes. Thus, different innovative approaches could be considered for AN or BQ research as use of these products has great historical, cultural, and social significance and there is a potential to be less harmful to humans.","PeriodicalId":331225,"journal":{"name":"Innovations in Digital Health, Diagnostics, and Biomarkers","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130955764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Data Protection in Healthcare-Integrated Biobanking 医疗一体化生物银行中的数据保护

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2023-01-01 DOI: 10.36401/iddb-22-7

P. Duhm-Harbeck, J. Habermann

{"title":"Data Protection in Healthcare-Integrated Biobanking","authors":"P. Duhm-Harbeck, J. Habermann","doi":"10.36401/iddb-22-7","DOIUrl":"https://doi.org/10.36401/iddb-22-7","url":null,"abstract":"\u0000 \u0000 \u0000 Development of personalized medicine depends on research using clinical biospecimens and data. This interface between clinical care and translational research is increasingly served by hospital-integrated biobanks; yet their implementation is hampered by complex data regulations.\u0000 \u0000 \u0000 \u0000 A generic data protection concept with a decision and application matrix was developed addressing five criteria: (1) organizational integration into university medicine, (2) biobank governance, (3) ethical and legal aspects, (4) specifications of the BSI (Bundesamt für Sicherheit in der Informationstechnik [Federal Office for Information Security]), and (5) FAIR (findable, accessible, interoperable, and reusable) principles for research data. Applicability was tested for the highest complexity level at Campus Lübeck.\u0000 \u0000 \u0000 \u0000 The data protection concept was approved by the local ethics committee as well as local and national data protection authorities. The concept allows an automated research-guided patient recruitment and data protection-compliant information technology (IT) in connection to national and international research networks. It ensures university and hospital conformity with the EU Data Protection Regulation. Consent behavior of 277,766 patients over five years proved routine practicability (error rate 0.0013%; withdrawals 0.09%). Clinical staff obtained higher consent rates (85.6%) compared with consent rates for use of data only at central patient admission (56.1%); even though consents in central patient admission increased constantly during observation time.\u0000 \u0000 \u0000 \u0000 The generic data protection concept can legitimately enable personalized medicine through biobanking in the clinical context.\u0000","PeriodicalId":331225,"journal":{"name":"Innovations in Digital Health, Diagnostics, and Biomarkers","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128528415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considerations on Digitizing Biomedical Research Infrastructures in Low- and Middle-Income Countries 关于中低收入国家生物医学研究基础设施数字化的思考

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2023-01-01 DOI: 10.36401/iddb-23-1

Anis Abboute, Sandra Nanyonga, F. Elkhwsky

引用次数: 0

Conception and Configuration of Biobank of CART Biospecimen Sets for Pediatrics Research 儿科研究CART生物标本集生物库的构想与配置

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2023-01-01 DOI: 10.36401/iddb-22-8

Min Wang, Shuang Li, Junmei Zhou

{"title":"Conception and Configuration of Biobank of CART Biospecimen Sets for Pediatrics Research","authors":"Min Wang, Shuang Li, Junmei Zhou","doi":"10.36401/iddb-22-8","DOIUrl":"https://doi.org/10.36401/iddb-22-8","url":null,"abstract":"\u0000 Biospecimen sets usually consist of various biospecimens collected in continuous clinical stages, carefully designed in advance by experts with diverse backgrounds according to the potential research purposes of translational medicine. This article reviews the importance and configuration of collecting biospecimen sets from CART clinical trials. A well-designed biospecimen collection plan must be considered seriously before implementing a genetically engineered chimeric antigen receptor T (CART) clinical trial. CART cells have been applied as the last line of defense for children with B-cell malignancies. Although some patients have experienced complete remission after receiving autologous and allogeneic CART cell infusions, challenges remain, particularly regarding the individual differences in curative efficacy. Further studies are needed based on a well-preserved biospecimen set, including an in-depth systematic review of the available data. It is essential and significant to preserve a small number of live CART cells after patients' infusion and collect other traditional forms of biospecimen, such as DNA and serum, from the cases at different stages of treatment, to establish a biobank of CART biospecimen set. This approach can be achieved through the top design of administrative management by integrating teams from both clinical practice and basic research, thus preventing the omission of important data and improper biospecimen preservation. Establishing a biobank of CART biospecimen set, which contains various types of biospecimen at different stages of treatment and the relevant clinical information, are valuable resources for the long-term follow-up study of prognosis and exploring the underlying mechanisms of individual differences of curative efficacy of CART clinical trials.","PeriodicalId":331225,"journal":{"name":"Innovations in Digital Health, Diagnostics, and Biomarkers","volume":"127 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115687324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Betel Nut and Arecoline: Past, Present, and Future Trends 槟榔和槟榔碱:过去，现在和未来的趋势

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2022-01-01 DOI: 10.36401/iddb-22-05

Z. Kozlakidis, I. Cheong, Hui Wang

引用次数: 2

Workshop Proceedings: Informed Consent in Biobanking–from the Key Barriers, Challenges, and Perceptions to Digital Innovations 研讨会论文集:生物银行的知情同意——从关键障碍、挑战和对数字创新的认知

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2022-01-01 DOI: 10.36401/iddb-21-07

D. Ivanova, P. Katsaounis

引用次数: 0

Highlights from 2022: Innovations in Digital Health, Diagnostics, and Biomarkers 2022年的亮点:数字健康、诊断和生物标志物的创新

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2022-01-01 DOI: 10.36401/iddb-22-x4

Z. Kozlakidis

引用次数: 0

Diversity Control in Early Transcribed ROS/RNS-balancing Genes: A Common Mechanism for Healthy Resilience? 早期转录ROS/ rns平衡基因的多样性控制:健康恢复力的共同机制?

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2022-01-01 DOI: 10.36401/iddb-22-03

B. Arnholdt‐Schmitt, Shahid Aziz, J. H. Costa

引用次数: 0

Efficient Rebalancing of ROS Levels in Plants Links to Temporarily Enhanced Aerobic Fermentation, Distinct Cell Restructuration, and Resilience in Field 植物体内活性氧水平的有效再平衡与暂时增强的好氧发酵、不同的细胞重组和田间恢复力有关

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2022-01-01 DOI: 10.36401/iddb-22-02

B. Arnholdt‐Schmitt, Shahid Aziz, J. H. Costa

引用次数: 0

Review of Innovative Immersive Technologies for Healthcare Applications 医疗保健应用的创新沉浸式技术综述

Innovations in Digital Health, Diagnostics, and Biomarkers Pub Date : 2022-01-01 DOI: 10.36401/iddb-21-04

Zhonglin Qu, Chng Wei Lau, S. Simoff, Paul J. Kennedy, Quang Vinh Nguyen, D. Catchpoole

{"title":"Review of Innovative Immersive Technologies for Healthcare Applications","authors":"Zhonglin Qu, Chng Wei Lau, S. Simoff, Paul J. Kennedy, Quang Vinh Nguyen, D. Catchpoole","doi":"10.36401/iddb-21-04","DOIUrl":"https://doi.org/10.36401/iddb-21-04","url":null,"abstract":"\u0000 Immersive technologies, including virtual reality (VR), augmented reality (AR), and mixed reality (MR), can connect people using enhanced data visualizations to better involve stakeholders as integral members of the process. Immersive technologies have started to change the research on multidimensional genomic data analysis for disease diagnostics and treatments. Immersive technologies are highlighted in some research for health and clinical needs, especially for precision medicine innovation. The use of immersive technology for genomic data analysis has recently received attention from the research community. Genomic data analytics research seeks to integrate immersive technologies to build more natural human-computer interactions that allow better perception engagements. Immersive technologies, especially VR, help humans perceive the digital world as real and give learning output with lower performance errors and higher accuracy. However, there are limited reviews about immersive technologies used in healthcare and genomic data analysis with specific digital health applications. This paper contributes a comprehensive review of using immersive technologies for digital health applications, including patient-centric applications, medical domain education, and data analysis, especially genomic data visual analytics. We highlight the evolution of a visual analysis using VR as a case study for how immersive technologies step, can by step, move into the genomic data analysis domain. The discussion and conclusion summarize the current immersive technology applications' usability, innovation, and future work in the healthcare domain, and digital health data visual analytics.","PeriodicalId":331225,"journal":{"name":"Innovations in Digital Health, Diagnostics, and Biomarkers","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128064245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5